LSG vs OAGB—1 Year Follow-up Data—a Randomized Control Trial
Autor: | Shivakumar Seetharamaiah, Tamonas Chaudhuri, Shashi Khanna, Om Tantia, Anmol Ahuja, Ghanshyam Goyal, Jagat Pal Singh |
---|---|
Rok vydání: | 2016 |
Předmět: |
Adult
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Gastric Bypass 030209 endocrinology & metabolism 1 year follow up Comorbidity Anastomosis law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Quality of life Gastrectomy law Weight loss Diabetes mellitus Weight Loss medicine Humans Prospective Studies Nutrition and Dietetics business.industry Type 2 Diabetes Mellitus Middle Aged medicine.disease Obesity Morbid Surgery Treatment Outcome Quality of Life Female Laparoscopy 030211 gastroenterology & hepatology medicine.symptom business Follow-Up Studies |
Zdroj: | Obesity Surgery. 27:948-954 |
ISSN: | 1708-0428 0960-8923 |
DOI: | 10.1007/s11695-016-2403-x |
Popis: | The objective of this study is to compare 3-year follow-up results of one anastomosis gastric bypass (MGB-OAGB) and laparoscopic sleeve gastrectomy (LSG) in terms of weight loss, complications, resolution of comorbidities and quality of life. A prospective randomised study of results between 100 LSG patients and 101 MGB-OAGB patients was done from 2012 to 2015. The results were compared regarding operative outcomes, percentage of excess weight loss (%EWL), complications, resolution of comorbidities and quality of life (BAROS score) at 3 years follow-up. Follow-up was achieved in 93 MGB-OAGB vs 92 LSG patients for 3-year period. The average %EWL for MGB-OAGB vs LSG was 66.48 vs 61.15% at the end of 3 years respectively, which was statistically insignificant. Diabetes remission was seen in 89.13% of MGB-OAGB patients and 81.82% of LSG patients. Remission of hypertension was seen in 74% of MGB-OAGB patients and 72.22% of LSG patients. Bariatric analysis reporting and outcome system (BAROS) with comorbidity in LSG patients and MGB-OAGB patients was 6.03 and 6.96 respectively, whereas in patients without comorbidity, BAROS score was 3.86 in LSG group and 4.34 in MGB-OAGB group. In our study, at 36 months follow up, there was no significant difference between LSG and MGB-OAGB in %EWL and remission of HTN. Type 2 diabetes mellitus (T2DM) remission rates were higher after MGB-OAGB as compared to LSG but the difference was statistically insignificant. MGB-OAGB patients with comorbidities have a better quality of life and BAROS score compared to LSG patients. |
Databáze: | OpenAIRE |
Externí odkaz: |